The European Commission approved Shire Plc�s $SHPG Marketing Authorization Application (MAA) seeking approval of ONIVYDE (pegylated liposomal irinotecan hydrochloride trihydrate) in combination with chemotherapy agents 5-fluorouracil (5-FU) and leucovorin (LV) for the treatment of adult patients with metastatic adenocarcinoma of the pancreas who have progressed after gemcitabine-based therapy. The approval comes after a positive CHMP opinion in July.